Isolated abnormalities in terminal regions of chromosomes 10q and 22q were formerly described in patients affected by neuropsychological impairment, abnormal facies, and heterogeneous structural abnormalities of the body. Chromosomes 10q and 22q harbor important genes that play a major role in CNS development, like DOCK1 and SHANK3, and in overall body growth, like FGFR2 and HTRA1. By using clinical, neuroradiological, neurophysiological, and genetic assessment, we studied 3 siblings affected by 2 different forms of very severe neuropsychological impairment with structural physical abnormalities, epilepsy, and body overgrowth. The genetic analysis revealed 2 different unbalanced translocations t(10;22)(q26.13;q13.32) of genetic material between the long arms of chromosomes 10 and 22, deriving from a maternal balanced translocation. Consequences of the unbalanced translocation were the simultaneous partial monosomy of 10q26.13 to 10qter and partial trisomy of 22q13.32 to 22qter in 2 patients and the simultaneous trisomy distal q10 and monosomy distal q22 in 1 patient, respectively. To the best of our knowledge, we here describe for the first time a causal association between an unbalanced translocation t(10;22) affecting the long arms of both chromosomes 10 and 22 and a very severe neurodevelopmental delay in 3 siblings.

Keywords:
Monosomy 10q26.13qter, Monosomy 22q13.32qter, Neurodevelopmental delay, Trisomy 10q26.13qter, Trisomy 22q13.32qter, Autism, Balanced and unbalanced translocation t(10;22)
1.
Barajas-Barajas LO, Valdez LL, Gonzalez JR, Garcia-Garcia C, Rivera H, Ramirez L: Sensorineural deafness in two infants: a novel feature in the 22q distal duplication syndrome. Cardinal signs in trisomies 22 subtypes. Genet Counsel 15:167-173 (2004).
2.
Battaglia A, Doccini V, Bernardini L, Novelli A, Loddo S, et al: Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features. Eur J Paediatr Neurol 17:589-599 (2013).
3.
Bonaglia MC, Giorda R, Borgatti R, Felisari G, Gagliardi C, et al: Disruption of the ProSAP2 gene in a t(12 ;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am J Hum Genet 69:261-268 (2001).
4.
Chen CP, Lin SP: Distal 10q trisomy associated with bilateral hydronephrosis in infancy. Genet Couns 14:359-362 (2003).
5.
Chen CP, Shih JC, Lee CC, Chen LF, Wang W, Wang TY: Prenatal diagnosis of a fetus with distal 10q trisomy. Prenat Diagn 19:876-878 (1999).
6.
Coci EG, Koehler U, Liehr T, Stelzner A, Fink C, et al: CANPMR syndrome and chromosome 1p32-p31 deletion syndrome coexist in two related individuals affected by simultaneous haplo-insufficiency of CAMTA1 and NIFA genes. Mol Cytogenet 9:10 (2016).
7.
Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, et al: Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 39:25-27 (2007).
8.
Feenstra I, Koolen DA, Van der Pas J, Hamel BC, Mieloo H, et al: Cryptic duplication of the distal segment of 22q due to a translocation (21;22): three case reports and a review of the literature. Eur J Med Genet 49:384-395 (2006).
9.
Goldberg-Stern H, Ganor Y, Cohen R, Pollak L, Teichberg V, Levite M: Glutamate receptor antibodies directed against AMPA receptors subunit 3 peptide B (GluR3B) associate with some cognitive/psychiatric/behavioral abnormalities in epilepsy patients. Psychoneuroendocrinology 40:221-231 (2014).
10.
Gonzales PR, Carroll AJ, Korf BR: Overview of clinical cytogenetics. Curr Protoc Hum Genet 89:8.1.1-8.1.13 (2016).
11.
Han K, Holder JL, Schaaf CP, Lu H, Chen H, et al: SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 503:72-77 (2013).
12.
Hasegawa H, Kiyokawa E, Tanaka S, Nagashima K, Gotoh N, et al: DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane. Mol Cell Biol 16:1770-1776 (1996).
13.
Liehr T, Claussen U: Current developments in human molecular cytogenetic techniques. Curr Mol Med 2:283-297 (2002).
14.
Manning MA, Cassidy SB, Clericuzio C, Cherry AM, Schwartz S, et al: Terminal 22q deletion syndrome: a newly recognized cause of speech and language disability in the autism spectrum. Pediatrics 114:451-457 (2004).
15.
Okamoto N, Kubota T, Nakamura Y, Murakami R, Nishikubo T, et al: 22q13 microduplication in two patients with common clinical manifestations: a recognizable syndrome? Am J Med Genet A 143A:2804-2809 (2007).
16.
Sheng M, Kim E: The Shank familiy of scaffold proteins. J Cell Sci 113:1851-1856 (2000).
17.
Tachibana M, Kiyokawa E, Hara S, Iemura S, Natsume T, et al: Ankyrin repeat domain 28 (ANKRD28), a novel binding partner of DOCK180, promotes cell migration by regulating focal adhesion formation. Exp Cell Res 315:863-876 (2009).
18.
Uchino S, Wada H, Honda S, Nakamura Y, Ondo Y, et al: Direct interaction of post-synaptic density-95/Dlg/ZO-1 domain-containing synaptic molecule Shank3 with GluR1 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor. J Neurochem 97:1203-1214 (2006).
19.
Vera-Carbonell A, López-González V, Bafalliu JA, Ballesta-Martínez MJ, Fernández A, et al: Clinical comparison of 10q26 overlapping deletions: delineating the critical region for urogenital anomalies. Am J Med Genet A 167A:786-790 (2015).
20.
Yatsenko SA, Kruer MC, Bader PI, Corzo D, Schuette J, et al: Identification of critical regions for clinical features of distal 10q deletion syndrome. Clin Genet 76:54-62 (2009).
21.
Wilson HL, Wong AC, Shaw SR, Tse WY, Stapleton GA, et al: Molecular characterization of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 40:575-584 (2003).
22.
Wong AC, Ning Y, Flint J, Clark K, Dumanski JP, et al: Molecular characterization of a 130-kb terminal microdeletion at 22q in a child with mild mental retardation. Am J Hum Genet 60:113-120 (1997).
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.